Immitra Bio is developing a platform for scalable, one-time curative in-vivo gene editing therapies based on its novel mutation-agnostic gene editing technology and digital target identification platform. The company is developing in-vivo gene editing therapies that do not require complex ex-vivo cell manipulation, patient conditioning, or stem cell transplantation.